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Synthesis of unusual isoxazoline containing β and γ-
dipeptides as potential glutamate receptor ligands 
Lucia Tamborini,a* Federica Mastronardi,a Federica Dall’Oglio,a Carlo De Micheli,a 
Birgitte Nielsen,b Leonardo Lo Presti,c Paola Contia and Andrea Pintoa 
New unconventional beta and gamma dipeptides, representing conformational constrained 
higher homologues of glutamic acid, have been prepared and tested as new pharmacological 
tools to investigate the iGluR binding domain, in the attempt to identify potential selective 
antagonists. 
 
Introduction 
L-Glutamic acid (L-Glu, Figure 1) is the main excitatory 
neurotransmitter in the central nervous system (CNS), where it 
is involved in the modulation of many physiological processes 
such as learning, memory, and synaptic plasticity.1 Once 
released from the presynaptic neurons into the glutamatergic 
synaptic cleft, L-Glu activates two main classes of receptors: G-
protein-coupled metabotropic Glu receptors (mGluRs) and 
ligand-gated ionotropic Glu receptors (iGluRs). On the basis of 
the agonist selectivity, iGluRs have been named N-methyl-D-
aspartic acid (NMDA) receptors, (RS)-2-amino-3-(3-hydroxy-
5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors, and 
kainic acid (KA) receptors.1-5 Each of these receptor classes is 
in turn composed of several receptor subtypes, depending on 
subunit composition.  
The availability of highly selective agonists and antagonists for 
the different receptor subtypes represents a primary target to 
understand their physiological role and their pharmacological 
relevance. Also from a therapeutic point of view, the more 
interesting compounds are undoubtedly those characterized by 
high selectivity for a specific receptor subtype, since this 
feature allows to minimize the possible side effects encountered 
with unselective compounds. 
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Starting from the structure of the endogenous ligand L-Glu, the 
more used molecular manipulation approaches to obtain potent 
and selective ligands are the conformational rigidification and 
the bioisosteric substitution, in particular on the distal 
carboxylate (e.g., phosphonic acid, tetrazol, 3-hydroxy-
isoxazole/isoxazoline).6 
In addition, homologation of the amino acidic chain is normally 
the strategy pursued to turn agonists into antagonists, because it 
prevents the closure of the clamshell like ligand binding 
domain (LBD), thus leaving the channel pore closed.7 Finally, it 
has to be highlighted that, whereas AMPA and KA receptor 
ligands are usually characterized by an S configuration at the α-
amino acid stereogenic center, in analogy to the natural ligands, 
NMDA receptors often exhibit a preference for R-configured 
amino acids, as in the case of the prototypical agonist NMDA. 
 
 
Figure 1. Structure of representative iGluR ligands. 
A simple chain homologation of glutamic acid leads to an 
increase of selectivity and to a switch of the pharmacological 
profile strictly related to the absolute configuration of the 
amino acidic C-α atom. Homologation of S-Glu leads to S-
amino adipic acid, which selectively activates mGluR2 and 
mGluR6, whereas it has no effect on mGluR1, mGluR4, or 
mGluR5. On the other hand, while R-Glu is inactive, the R 
enantiomer of amino adipic acid behaves as a competitive 
NMDA receptor antagonist, even if with low potency. Very 
interestingly, bioisosteric substitution of the distal carboxylic 
group with a phosphonic acid group generates to potent and 
Page 1 of 7 MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
15
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
26
/0
5/
20
15
 0
8:
10
:4
2.
 
View Article Online
DOI: 10.1039/C5MD00159E
ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
selective competitive antagonists for the NMDA receptor, i.e., 
(R)-2-amino-5-phosphonopentanoic acid (R-AP-5). Further 
extension of the backbone chain length gives another potent 
NMDA antagonist, i.e., (R)-2-amino-5-phosphonoheptanoic 
acid (R-AP-7) (Figure 1).8 
On this ground, we planned the synthesis of a series of unusual 
isoxazoline containing dipeptides as higher homologues of 
glutamic acid, i.e., compounds 1a, 1b, 2a and 2b (Figure 2), in 
which the distal carboxylate of glutamic acid was condensed to 
unconventional isoxazoline-containing beta or gamma amino 
acids. In this way, we generated partially constrained glutamic 
acid homologues, of different length, possessing the suitable 
characteristics to be considered potential selective Glu receptor 
antagonists (i.e., increased chain length and conformational 
rigidification). Notably, whereas compounds 2a and 2b have a 
carboxylate function in the distal position, mimicking that of L-
Glu, in compounds 1a and 1b the distal acidic group, which is 
one of the essential pharmacophoric groups, is represented by 
the 3-hydroxy-isoxazoline ring, which has already proved to 
behave as a γ-COOH bioisostere (Figure 2).9 
  
 
 
Figure 2. Structure of the target compounds. 
Results and discussion  
Dipeptides (‒)-1a, (+)-1a, (‒)-1b and (+)-1b were synthetized 
from the enantiomerically pure compounds (‒)-3 and (+)-3, 
which were obtained as recently reported by us.10 Intermediates 
(‒)-3 and (+)-3 were submitted to a nucleophilic substitution at 
the C-3, in the presence of benzyl alcohol and sodium hydride, 
to obtain the desired 3-benzyloxy-substituted intermediates (‒)-
4 and (+)-4, respectively.9b,11 After N-Boc deprotection with a 
30% trifluoroacetic acid solution in dichloromethane, the free 
amines were coupled with the suitable protected Boc-L-Glu-
OEt or Boc-D-Glu-OEt, obtained in good yield and high purity 
following a literature procedure,12 using HOBt and HBTU as 
coupling reagents (Scheme 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: a) BnOH, NaH 60% in mineral oil, dry THF; 
b) 30% TFA, CH2Cl2 c) Boc-L-Glu-OEt or Boc-D-Glu-OEt, HOBt, HBTU, 
DIPEA; CH2Cl2; d) 1N NaOH, EtOH e) H2, 5% Pd/C, MeOH. 
The final dipeptides (‒)-1a, (+)-1a, (‒)-1b and (+)-1b were 
obtained after deprotection of intermediates (‒)-5a, (+)-5a, (‒)-
5b and (+)-5b. In particular, after the hydrolysis of the amino 
acidic ester with 1N NaOH at room temperature, the O-benzyl 
group was removed by catalytic hydrogenation with 5% Pd/C. 
Finally, treatment with a 30% trifluoroacetic acid solution in 
CH2Cl2 gave the final desired compounds. The substitution of 
the Br in the C-3 position with the benzyloxy group, a precursor 
of the desired hydroxyl function, was necessary since the direct 
substitution with the OH group (treating with 1N NaOH at 60 
°C) led to degradation of the dipeptidic structure. 
The synthesis of compounds (‒)-2a, (+)-2a, (‒)-2b and (+)-2b 
was accomplished starting from cycloadducts (‒)-7 or (+)-7, 
which were obtained through resolution of the corresponding 
racemic mixture (±)-7, by chiral semi-preparative HPLC. 
Compound (±)-7 was synthetized in a flow chemistry reactor 
exploiting the 1,3-dipolar cycloaddition reaction of the 
dipolarophile 6 with ethoxycarbonyl formonitrile oxide, 
generated in situ by treatment of ethyl 2-chloro-2-
(hydroxyimino)acetate with solid potassium carbonate, 
following a procedure recently reported by us (Scheme 2).13 An 
excellent enantiomeric separation (e.e. >99%) of racemic (±)-7 
was achieved using a tris-(2-methyl-5-chloro-phenyl)carbamoyl 
amylose chiral stationary phase.   
 
 
 
 
 
 
 
 
 
 
Scheme 2. a) Semi-preparative HPLC separation; chiral stationary phase: tris-(2-
methyl-5-chloro-phenyl)carbamoyl amylose; eluent: 7:3 n-hexane/iPrOH; flow 
rate: 15 mL/min. 
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On both the enantiomers (‒)-7 and (+)-7, the N-Boc protecting 
group was removed under standard conditions to yield the 
corresponding free amines that were used for the coupling 
reaction with the protected L-Glu or D-Glu derivative (Scheme 
3), as described above. Intermediates were finally deprotected 
to obtain the desired products (‒)-2a, (+)-2a, (‒)-2b and (+)-2b. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions. a) 30% TFA, CH2Cl2 b) Boc-L-Glu-OEt or 
Boc-D-Glu-OEt, HOBt, HBTU, DIPEA; CH2Cl2; c) 1N NaOH, EtOH. 
Whereas the absolute configuration of derivatives 1 was 
determined by the know configurations of the two building 
blocks (i.e., the amine and the amino acidic portion), the 
absolute configurations of compounds 2 had to be assigned and 
it was determined by X-ray analysis of the final compound (+)-
2b. Despite the lack of anomalous scatterers in the unit cell, 
being the absolute configuration at the α amino acidic carbon 
known to be S, it was sufficient to determine the relative 
configuration of the three stereogenic centers, to unequivocally 
assign the absolute configuration (2S,7S,8R) to the enantiomer 
(+)-2b (Figure 3). Consequently, the absolute configuration to 
derivatives (−)-2b, (+)-2a and (−)-2a was assigned. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Asymmetric unit of (+)-2b, with the atom numbering scheme. A co-
crystallized, ordered water molecule is also present. Thermal ellipsoids at RT 
were drawn at the 50 % probability level. 
All the new compounds were preliminary submitted to binding 
assays at native iGluRs, using rat brain synaptic membranes 
from male Sprague–Dawley rats. Affinities for NMDA, AMPA, 
and KA receptors were determined using 2 nM [3H]CGP39653, 
5 nM [3H]AMPA, and 5 nM [3H]KA (Table 1).14  
 
Table 1. Receptor binding affinities at native rat iGluRs.a 
Cmpd [
3H]AMPA 
IC50 (µM) 
[3H]KAIN       
IC50 (µM) 
[3H]CGP39653   
Ki (µM) 
(‒)-1a 43 [4.37±0.01] 37 [4.43±0.05] 25 [4.63±0.08] 
(+)-1a > 100 > 100 > 100 
(‒)-1b > 100 > 100 > 100 
(+)-1b 48 [4.36±0.12] 59 [4.23±0.01] 41 [4.41±0.08] 
(‒)-2a 46 [4.34±0.02] 66 [4.20±0,11] 24 [4.64±0.10] 
(+)-2a > 100 > 100 58[4.24±0.04] 
(‒)-2b 34 [4.48±0.06] 40 [4.39±0.01] 21 [4.68±0.03] 
(+)-2b 67 [4.18±0.03] 56 [4.25±0.03] 28 [4.56±0.07] 
a Data are given as mean [pIC50 mean ± SEM or pKi mean ± SEM] of 
three independent experiments each conducted in triplicate. 
 
Unfortunately, pharmacologically investigation at native 
iGluRs did not highlight any ligand endowed with a worth 
noting affinity or selectivity for a specific iGlu receptor. In fact, 
most compounds showed a mid-micromolar affinity for all iGlu 
receptors. As expected, with the only exception of (−)-2b, 
compounds having an R configuration at the α-amino acidic 
center did not interact with AMPA and KA receptors; (+)-2a 
weakly bound to NMDA receptors. Conversely, all compounds 
derived from L-Glu showed a comparable profile, which was 
not significantly affected by the absolute configuration of the 
bicyclic scaffold. Functional studies as well as activity at 
mGluRs remain to be investigated. 
Conclusions 
New unconventional beta and gamma dipeptides, representing 
conformational constrained higher homologues of glutamic 
acid, have been prepared and tested as new pharmacological 
tools to investigate the iGluR binding domain, in the attempt to 
identify potential selective antagonists. The rationale was based 
on the use of classical medicinal chemistry strategies, widely 
applied in the design of glutamatergic ligands. The synthesis 
entailed the use of a flow-chemistry reactor to perform the 1,3-
dipolar cycloaddition to build the rigid isoxazoline bicyclic 
scaffolds, which were then condensed to the distal carboxylate 
of L-Glu or D-Glu. All the new derivatives were obtained in 
enantiomerically pure form and assignment of the absolute 
configuration relied on X-ray crystal analysis. Based on the 
available pharmacological data, we can speculate that the 
conformational constraint imposed by the bicyclic scaffold, 
which was meant to increase the receptor selectivity, did not 
favour the correct orientation of the pharmacophoric groups for 
a fruitful interaction with the D1 and D2 lobes of iGluRs. 
Alternatively, the distance between the α-amino acidic group 
and the distal carboxylate may not be optimal. To deepen this 
particular aspect, shorter derivatives may be designed by 
substituting L-Asp (or D-Asp) for L-Glu (or D-Glu).  
Experimental  
Materials and methods 
All reagents were purchased from Sigma. 1H NMR and 13C 
NMR spectra were recorded with a Varian Mercury 300 (300 
MHz) spectrometer. Chemical shifts (δ) are expressed in ppm, 
and coupling constants (J) are expressed in Hz. Optical rotation 
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determinations were carried out using a Jasco P-1010 
spectropolarimeter, coupled with a Haake N3-B thermostat. 
TLC analyses were performed on commercial silica gel 60 F254 
aluminium sheets; spots were further evidenced by spraying 
with a dilute alkaline potassium permanganate solution or 
ninhydrin. Chiral HPLC analyses were performed with a Jasco 
PU-980 pump equipped with a UV–vis detector Jasco UV-975 
(wavelength: 220 nm) and a Phenomenex Lux Amylose-2 
column (4.6 × 150 mm, 5 µm) at a flow rate of 1 mL/min using 
n-hexane/iPrOH 8:2 as eluent. Preparative HPLC was 
performed with a 1525 Extended Flow Binary HPLC Pump, 
equipped with a Waters 2489 UV-vis detector and a 
Phenomenex Lux Amylose-2 column (21.2 × 250 mm) at a 
flow rate of 15 mL/min using n-hexane/iPrOH 7:3 as eluent. 
MS analyses were performed on a Varian 320-MS triple 
quadrupole mass spectrometer with ESI source. Microanalyses 
(C, H, N) of new compounds were within ±0.4% of theoretical 
values. The continuous-flow cycloaddition reaction was 
performed using a R2+/R4 flow reactor, commercially available 
from Vapourtec equipped with Omnifit glass column. 
Cycloadduct (−)-3 and its enantiomer (+)-3 were prepared as 
previously reported by us.10 
 
General procedure for the nucleophilic substitution 
To a solution of benzyl alcohol (1.45 mL, 14.0 mmol) in dry 
THF (50 mL), NaH (60% dispersion in mineral oil; 7.0 mmol) 
was added in small portions and the mixture was stirred at rt 
under a nitrogen atmosphere for 30 min. A solution of 3-Br-
isoxazoline derivative 3 (2.3 mmol) in dry THF (3.7 mL) was 
then added and the mixture was refluxed for 3 h. The progress 
of the reaction was monitored by TLC (cyclohexane/EtOAc 
8:2). The reaction was quenched with 2N HCl (5 mL) and, after 
evaporation of the solvent, the aqueous layer was extracted with 
Et2O (3 × 10 mL). The organic phase was dried over Na2SO4 
and concentrated under vacuum. The residue was then purified 
by flash chromatography (cyclohexane/EtOAc 9:1). 
(3aR,6aR)-tert-Butyl 3-(benzyloxy)-6,6a-dihydro-3aH-
pyrrolo[3,4-d]isoxazole-5(4H)-carboxylate (−)-4. 
Yield: 94%; Rf = 0.28 (cyclohexane/EtOAc 8:2); crystallized 
from n-hexane/EtOAc as colourless prisms; m.p.: 152-153 °C; 
[α]20D= – 90.1 (c = 0.85 in CHCl3); 1H-NMR (300 MHz, 
CDCl3): 1.45 (s, 9H); 3.41 (dd, J = 8.3, 12.8, 1H); 3.48−3.62 
(m, 1H); 3.75 (ddd, J = 2.2, 8.3, 8.3, 1H); 3.83 (dd, J = 1.9, 
12.8, 1H); 3.88−4.02 (m, 1H); 5.14 (s, 2H); 5.21 (ddd J = 1.9, 
6.1, 8.3, 1H); 7.35−7.42 (m, 5H); 13C-NMR (75 MHz, CDCl3): 
28.60; 48.24; 49.29; 53.87; 72.69; 80.40; 84,81; 128.59; 
128.86; 128.90; 135.50; 154.23; 166.93; MS: 319.2 [M+H]+; 
Anal. calcd for C17H22N2O4: C, 64.13; H, 6.97; N, 8.80; found: 
C, 63.84; H, 7.03; N, 8.70 
(3aS,6aS)-tert-Butyl 3-(benzyloxy)-6,6a-dihydro-3aH-
pyrrolo[3,4-d]isoxazole-5(4H)-carboxylate (+)-4. 
[α]20D= + 90.4 (c = 0.90 in CHCl3); Anal. calcd for 
C17H22N2O4: C, 64.13; H, 6.97; N, 8.80; found: C, 63.90; H, 
7.00; N, 8.68. 
 
 
General procedure for the coupling reaction. 
a) Boc-protected secondary amine 4 (2.0 mmol) was treated 
with a 30% solution of trifluoroacetic acid (20.0 mmol) in 
CH2Cl2 at 0 °C and the solution was stirred at rt for 4 h. The 
volatiles were removed under vacuum, 1N NaOH (5 mL) was 
added and the aqueous layer was extracted with CH2Cl2 (3 × 20 
mL). The organic layer was dried over anhydrous Na2SO4, 
filtered, evaporated to dryness and the residue was purified by 
flash chromatography (CH2Cl2/MeOH 9:1). 
b) Boc-L-Glu-OEt or Boc-D-Glu-OEt (1.0 mmol) was dissolved 
in CH2Cl2 (2.0 mL). HOBt hydrate (2.0 mmol), HBTU (2.0 
mmol), DIPEA (2.0 mmol) and a solution of the amine obtained 
in the previous step (1.0 mmol) in CH2Cl2 (0.5 mL) were added 
to the solution. Then the reaction was stirred at rt for 24 h. The 
progress of the reaction was monitored by TLC 
(cyclohexane/EtOAc 3:7). After removal of the solvent, the 
residue was diluted with EtOAc (5 mL) and the organic phase 
was washed with distilled H2O (5 mL), dried over Na2SO4 and 
concentrated under vacuum. The crude material was purified by 
flash chromatography (cyclohexane/EtOAc 3:7). 
(S)-Ethyl 5-((3aR,6aR)-3-(benzyloxy)-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-2-(tert-butoxycarbonylamino)-
5-oxopentanoate (−)-5a. 
Overall yield: 60%; Rf = 0.30 (cyclohexane/EtOAc 9:1); 
crystallized from n-hexane/EtOAc as colourless prisms; m.p.: 
138-140 °C [α]20D= – 61.7 (c = 0.5 in CHCl3); 1H-NMR (300 
MHz, CDCl3): 1.18–1.34 (m, 3H); 1.40–1.52 (m, 9H); 1.84–
2.10 (m, 1H); 2.10–2.55 (m, 3H); 3.40–3.73 (m, 2H); 3.74–4.07 
(m, 3H); 4.13–4.33 (m, 3H); 5.10–5.14 (m, 2H); 5.22–5.34 (m, 
2H); 7.34–7.42 (m, 5H); 13C-NMR (75 MHz, CDCl3): 14.39; 
27.71; 28.54; 31.01; 47.92; 48.54; 50.10; 53.87; 61.68; 72.84; 
80.10; 84.85; 128.62; 128.90; 129.08; 135.30; 155.80; 166.92; 
170.93; 172.55; MS: 476.3 [M+H]+; Anal. calcd for 
C24H33N3O7: C, 60.62; H, 6.99; N, 8.84; found: C, 60.84; H, 
7.03; N, 8.80. 
(R)-Ethyl 5-((3aS,6aS)-3-(benzyloxy)-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-2-(tert-butoxycarbonylamino)-
5-oxopentanoate (+)-5a. 
[α]20D= + 62.1 (c = 0.5 in CHCl3); Anal. calcd for C24H33N3O7: 
C, 60.62; H, 6.99; N, 8.84; found: C, 60.80; H, 7.03; N, 8.78. 
(S)-Ethyl 5-((3aS,6aS)-3-(benzyloxy)-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-2-(tert-butoxycarbonylamino)-
5-oxopentanoate (+)-5b. 
Overall yield: 58%; Rf = 0.30 (cyclohexane/EtOAc 9:1); 
crystallized from n-hexane/EtOAc as colourless prisms; m.p.: 
45-47 °C [α]20D= + 83.7 (c = 0.55 in CHCl3); 1H-NMR (300 
MHz, CDCl3): 1.20–1.32 (m, 3H); 1.41–1.50 (m, 9H); 1.81–
2.09 (m, 1H); 2.10–2.42 (m, 3H); 3.40–3.70 (m, 2H); 3.70–4.10 
(m, 3H); 4.18–4.35 (m, 3H); 5.09–5.20 (m, 2H), 5.20–5.34 (m, 
2H); 7.32–7.42 (m, 5H); 13C-NMR (75 MHz, CDCl3): 14.41; 
27.77; 28.54; 30.78; 47.93; 48.57; 50.10; 53.79; 61.70; 72.82; 
80.16; 84.89; 128.60; 128.91; 129.09; 135.30; 155.83; 166.97; 
170.85; 172.63; MS: 476.3 [M+H]+; Anal. calcd for 
C24H33N3O7: C, 60.62; H, 6.99; N, 8.84; found: C, 60.88; H, 
7.06; N, 8.74. 
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(R)-Ethyl 5-((3aR,6aR)-3-(benzyloxy)-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-2-(tert-butoxycarbonylamino)-
5-oxopentanoate (−)-5b. 
[α]20D= ‒ 84.0 (c = 0.50 in CHCl3); Anal. calcd for C24H33N3O7: 
C, 60.62; H, 6.99; N, 8.84; found: C, 60.80; H, 7.04; N, 8.72. 
 
General deprotection procedure 1. 
a) Protected intermediate 5a or 5b (0.4 mmol) was dissolved in 
EtOH (1.2 mL) and treated with 1N aqueous NaOH (0.6 mL). 
The mixture was stirred at rt for 1 h and the disappearance of 
the starting material was monitored by TLC 
(cyclohexane/EtOAc 3:7). After evaporation of EtOH, the 
aqueous layer was washed with Et2O (3 mL), made acidic (pH 
= 2) with 2N aqueous HCl and extracted with EtOAc (3 × 10 
mL). The organic phase was dried over Na2SO4 and 
concentrated under vacuum.  
b) The crude acidic product obtained in the previous step was 
dissolved in MeOH (3 mL) and 10% w/w of 5% Pd/C was 
added. The mixture was stirred at rt for 30 min under H2 
atmosphere and the reaction was followed by TLC 
(CH2Cl2/MeOH 9:1 + 1% AcOH). The mixture was filtered 
under vacuum on a celite pad to eliminate the catalyst, and the 
solvent was removed under reduced pressure. 
c) The obtained intermediate was treated with a 30% 
trifluoroacetic acid (10 eq.) solution in CH2Cl2 at 0 °C. The 
solution was stirred at rt for 3 h and the reaction was followed 
by TLC (CH2Cl2/MeOH 9:1 + 1% AcOH). The volatiles were 
removed under reduced pressure and the solid residue was 
taken up with MeOH and filtered. 
(S)-2-Amino-5-((3aR,6aR)-3-hydroxy-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-5-oxopentanoic acid (−)-1a. 
Overall yield: 45%; Rf = 0.11 (n-butanol/H2O/AcOH 4:2:1); 
white solid; m.p.: T > 60 °C dec.; [α]20D= – 14.0 (c = 0.12 in 
H2O); 1H-NMR (300 MHz, D2O): 2.02–2.14 (m, 2H); 2.38–
2.62 (m, 2H) 3.44–3.94 (m, 5H); 5.26–5.38 (m, 1H); 13C-NMR 
(75 MHz, CDCl3): 25.20; 29.95; 46.18; 47.51; 51.88; 52.94; 
82.99; 161.80; 172.59; 172.96; MS: 258.1 [M+H]+; Anal. calcd 
for C10H15N3O5: C, 46.69; H, 5.88; N, 16.33; found: C, 46.55; 
H, 5.98; N, 16.08. 
(R)-2-Amino-5-((3aS,6aS)-3-hydroxy-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-5-oxopentanoic acid (+)-1a. 
[α]20D= + 14.1 (c = 0.15 in H2O); Anal. calcd for C10H15N3O5: 
C, 46.69; H, 5.88; N, 16.33; found: C, 46.59; H, 5.96; N, 16.12. 
(S)-2-Amino-5-((3aS,6aS)-3-hydroxy-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-5-oxopentanoic acid (+)-1b. 
Yield: 48%; white solid; Rf = 0.11 (n-butanol/H2O/AcOH 
4:2:1); m.p.: T > 60 °C dec.; [α]20D = +51.9 (c = 0.14 in H2O); 
1H NMR (300 MHz, D2O): 2.00–2.15 (m, 2H); 2.40–2.62 (m, 
2H); 3.45–3.98 (m, 5H); 5.25–5.40 (m, 1H); 13C-NMR (75 
MHz, CDCl3): 25.20; 29.95; 46.18; 47.37; 51.47; 53.15; 82.35; 
163.80; 172.59; 172.96; MS: 258.1 [M+H]+; Anal. calcd for 
C10H15N3O5: C, 46.69; H, 5.88; N, 16.33; found: C, 46.45; H, 
6.08; N, 16.04. 
(R)-2-Amino-5-((3aR,6aR)-3-hydroxy-3aH-pyrrolo[3,4-
d]isoxazol-5(4H,6H,6aH)-yl)-5-oxopentanoic acid (−)-1b. 
[α]20D = – 51.5 (c = 0.15 in H2O); Anal. calcd for C10H15N3O5: 
C, 46.69; H, 5.88; N, 16.33; found: C, 46.50; H, 6.05; N, 16.10. 
 
Synthesis of (3aS,6aR)-5-tert-butyl 3-ethyl 6,6a-dihydro-
3aH-pyrrolo[3,4-d]isoxazole-3,5(4H)-dicarboxylate (‒)-7 
and (3aR,6aS)-5-tert-butyl 3-ethyl 6,6a-dihydro-3aH-
pyrrolo[3,4-d]isoxazole-3,5(4H)-dicarboxylate (+)-7. 
A 0.25 M solution of compound 6 (1.0 mmol) in EtOAc (4 mL) 
and a 0.37 M solution of ethyl chlorooximinoacetate (1.5 
mmol) in EtOAc (4 mL) were prepared. The two reactant 
streams were mixed using a simple T-piece and delivered to a 
glass column (6.6 mm i.d.× 100 mm length) filled with K2CO3 
and heated at 80 °C at a total flow rate of 0.16 mL min-1, 
equating to a residence time of about 20 min. A 100 psi 
backpressure regulator was applied to the system. The solvent 
was evaporated, and the crude material was purified by silica 
gel column chromatography (cyclohexane–EtOAc 8:2) to yield 
racemic (±)-7 in 62% yield. Yellow oil; Rf = 0.17 
(cyclohexane/EtOAc 8:2): 0.17; 1H-NMR (300 MHz, CDCl3): 
1.35 (t, J = 7.2 Hz, 3H), 1.42 (s, 9H), 3.41–3.54 (m, 2H), 3.79–
4.08 (m, 1H), 3.80–4.10 (m, 2H), 4.35 (q, J = 7.2 Hz, 2H), 5.32 
(dd, J = 5.4, 9.6 Hz, 1H); 13C-NMR (75 MHz, CDCl3): 14.26; 
28.48; 49.49; 50.75; 53.44; 62.45; 80.59; 87,74; 152.52; 
154.28; 160.36; MS: 285.0 [M+H]+. 
Enantiomerically pure (‒)-7 and (+)-7 were obtained from (±)-7 
by preparative chiral HPLC. Column: Lux 2-amycoat (21.2 × 
250 mm, 5 µm); λ = 220 nm; eluent: n-hexane/iPrOH 7:3; flow 
rate: 15 mL/min; tr (‒)-9: 9.58 min; tr (+)-9: 13.40 min. 
(‒)-7: [α]20D = ‒ 172.4 (c = 0.76 in CHCl3). 
(+)-7: [α]20D =+173.0 (c = 0.74 in CHCl3). 
 
(3aS,6aR)-Ethyl 5-((S)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanoyl)-4,5,6,6a-tetrahydro-3aH-
pyrrolo[3,4-d]isoxazole-3-carboxylate (−)-8a. 
Compound (−)-8a was obtained following the general 
procedure for the coupling reaction reported above, coupling 
(‒)-7 with Boc-L-Glu-OEt. 
Overall yield: 44%; yellow oil; Rf = 0.30 (cyclohexane/EtOAc 
3:7); [α]20D= – 131.9 (c = 0.10 in CHCl3); 1H-NMR (300 MHz, 
CD3OD): 1.26 (t, J = 7.15, 3H); 1.30–1.38 (m, 3H); 1.43 (s, 
9H); 1.78–1.96 (m, 1H); 2.02–2.16 (m, 1H); 2.30–2.56 (m, 2H); 
3.44–3.62 (m, 1H); 3.68–3.80 (m, 1H) 3.84–4.40 (m, 1H); 
4.02–4.24 (m, 5H); 4.26–4.38 (m, 2H); 5.37–5.50 (m, 1H); 
6.92–7.02 (m, 1H); 13C-NMR (75 MHz, CD3OD): 13.22; 13.38; 
26.51; 27.57; 49.69; 49.82; 51.31; 52.56; 53.53; 61.14; 62.04; 
79.46; 87.48; 152.80; 156.89; 160.31; 171.93; 172.79; MS: 
442.4 [M+H]+; Anal. calcd for C20H31N3O8: C, 54.41; H, 7.08; 
N, 9.52; found: C, 54.50; H, 7.05; N, 9.25. 
(3aR,6aS)-Ethyl 5-((R)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanoyl)-4,5,6,6a-tetrahydro-3aH-
pyrrolo[3,4-d]isoxazole-3-carboxylate (+)-8a. 
Compound (+)-8a was obtained following the general 
procedure for the coupling reaction reported above, coupling 
(+)-7 with Boc-D-Glu-OEt. 
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[α]20D= + 132.5 (c = 0.10 in CHCl3); Anal. calcd for 
C20H31N3O8: C, 54.41; H, 7.08; N, 9.52; found: C, 54.20; H, 
7.00; N, 9.30. 
(3aR,6aS)-Ethyl 5-((S)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanoyl)-4,5,6,6a-tetrahydro-3aH-
pyrrolo[3,4-d]isoxazole-3-carboxylate (+)-8b. 
Compound (+)-8b was obtained following the general 
procedure for the coupling reaction reported above, coupling 
(+)-7 with Boc-L-Glu-OEt. 
Overall yield: 48%; yellow oil; Rf = 0.30 (cyclohexane/EtOAc 
3:7); [α]20D= + 120.5 (c = 0.10 in CHCl3); 1H-NMR (300 MHz, 
CD3OD): 1.26 (t, J = 7.2, 3H); 1.30–1.38 (m, 3H); 1.42 (s, 9H); 
1.80–1.96 (m, 1H); 2.00–2.18 (m, 1H); 2.30–2.54 (m, 2H); 
3.42–3.62 (m, 1H); 3.68–3.80 (m, 1H); 3.84–4.26 (m, 6H); 
4.26–4.40 (m, 2H) 5.38–3.50 (m, 1H); 6.92–7.02 (m, 1H); 13C-
NMR (75 MHz, CD3OD): 13.19; 13.34; 26.53; 27.53; 49.71; 
49.83; 51.28; 52.51; 53.57; 61.14; 62.03; 79.46; 86.48; 152.81; 
156.94; 160.30; 171.97; 172.81; MS: 442.4 [M+H]+; Anal. 
calcd for C20H31N3O8: C, 54.41; H, 7.08; N, 9.52; found: C, 
54.35; H, 6.98; N, 9.38. 
(3aS,6aR)-Ethyl 5-((R)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanoyl)-4,5,6,6a-tetrahydro-3aH-
pyrrolo[3,4-d]isoxazole-3-carboxylate (−)-8b. 
Compound (−)-8b was obtained following the general 
procedure for the coupling reaction reported above, coupling 
(‒)-7 with Boc-D-Glu-OEt. 
[α]20D= ‒ 122.0 (c = 0.15 in CHCl3); Anal. calcd for 
C20H31N3O8: C, 54.41; H, 7.08; N, 9.52; found: C, 54.25; H, 
6.94; N, 9.40. 
 
General deprotection procedure 2. 
a) Protected intermediate 8a or 8b (0.4 mmol) was dissolved in 
EtOH (1.2 mL) and treated with 1N aqueous NaOH (1.2 mL). 
The mixture was stirred at rt for 1 h and the disappearance of 
the starting material was monitored by TLC 
(cyclohexane/EtOAc 3:7). After evaporation of EtOH, the 
aqueous layer was washed with Et2O (3 mL), made acidic (pH 
= 2) with 2N aqueous HCl and extracted with EtOAc (3 × 10 
mL). The organic phase was dried over Na2SO4 and 
concentrated under vacuum.  
b) The diacidic product obtained in the previous step was 
treated with a 30% trifluoroacetic acid (10 eq.) solution in 
CH2Cl2 at 0 °C. The solution was stirred at rt for 3 h and the 
reaction was followed by TLC (CH2Cl2/MeOH 9:1 + 1% 
AcOH). The volatiles were removed under reduced pressure 
and the solid residue was taken up with MeOH and filtered. 
(3aS,6aR)-5-((S)-4-Amino-4-carboxybutanoyl)-4,5,6,6a-
tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-3-carboxylic acid (–
)-2a. 
Overall yield: 55%; white solid; Rf = 0.11 (n-
butanol/H2O/AcOH 4:2:1); m.p.: T > 80 °C dec.; [α]20D= – 
100.8 (c = 0.10 in H2O); 1H-NMR (300 MHz, D2O): 1.94–2.12 
(m, 2H); 2.34–2.60 (m, 2H); 3.36–3.52 (m, 1H); 3.60–3.74 (m, 
1H); 3.78–4.00 (m, 3H); 4.04–4.20 (m, 1H); 5.30–5.46 (m, 1H); 
13C-NMR (75 MHz, D2O): 25.33; 30.09; 48.87; 50.15; 51.72; 
52.99; 53.89; 86.95; 156.47; 164.37; 172.61; 172.69; MS: 286.0 
[M+H]+; Anal. calcd for C11H15N3O6: C, 46.32; H, 5.30; N, 
14.73; found: C, 46.52; H, 5.50; N, 14.53. 
(3aR,6aS)-5-((R)-4-Amino-4-carboxybutanoyl)-4,5,6,6a-
tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-3-carboxylic acid 
(+)-2a. 
[α]20D= + 101.2 (c = 0.10 in H2O); Anal. calcd for C11H15N3O6: 
C, 46.32; H, 5.30; N, 14.73; found: C, 46.49; H, 5.48; N, 14.58. 
(3aR,6aS)-5-((S)-4-Amino-4-carboxybutanoyl)-4,5,6,6a-
tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-3-carboxylic acid 
(+)-2b 
Overall yield: 62%; white solid; Rf = 0.1 (n-butanol/H2O/AcOH 
4:2:1); m.p.: T > 80 °C dec.; [α]20D= + 125.7 (c = 0.10 in H2O); 
1H-NMR (300 MHz, D2O): 1.94–2.12 (m, 2H); 2.38–2.62 (m, 
2H); 3.37–3.52 (m, 1H); 3.62–3.74 (m, 1H); 3.78–4.00 (m, 3H); 
4.04–4.20 (m, 1H); 5.28–5.44 (m, 1H); 13C-NMR (75 MHz, 
D2O): 25.25; 30.03; 49.34; 50.91; 52.81; 53.89; 87.05; 156.20; 
164.04; 172.45; 172.73; MS: 286.0 [M+H]+; Anal. calcd for 
C11H15N3O6: C, 46.32; H, 5.30; N, 14.73; found: C, 46.45; H, 
5.53; N, 14.48. 
(3aS,6aR)-5-((R)-4-Amino-4-carboxybutanoyl)-4,5,6,6a-
tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-3-carboxylic acid (–
)-2b 
[α]20D= – 124.6 (c = 0.10 in H2O); Anal. calcd for C11H15N3O6: 
C, 46.32; H, 5.30; N, 14.73; found: C, 46.48; H, 5.50; N, 14.52. 
 
X-ray diffraction analysis of (+)-2b.  
Well-formed colorless crystals of the compound (+)-2b were 
grown by slow evaporation (≈ 7 d) from a 1:1 mixture of 
H2O:CH3CN. A transparent thin plate (0.225 × 0.175 × 0.025 
mm) was selected for the analysis and mounted on a glass 
capillary fiber with perfluorinated oil as glue. X-ray diffraction 
intensities were collected at room temperature on a three-circle 
Bruker SMART APEX II diffractometer equipped with a CCD 
area detector. The data collection consisted of 5 ω-scans (0.5 
deg/frame, with exposure time ranging from 60 to 90 s/frame) 
at different ɸ orientations of the crystal. Graphite-
monochromated Mo Kα radiation (λ = 0.71073 Å) was 
employed throughout. A 100 % complete dataset up to a 
maximum Bragg angle 2ϑ = 55° was obtained, consisting of 
19388 measured reflections (2982 symmetry-independent). 
Data reduction and correction for beam anisotropy effects were 
performed by SAINT+ and SADABS, respectively.15,16 The 
structure was solved by direct methods through SHELXS–
201316 and refined by the full-matrix least-squares procedure 
implemented in SHELXL–2014/4.17,18 The agreement factors 
for the final least-squares model were R1(F) = 0.0496 for 1573 
Fo > 4σ(Fo) and wR(F2)= 0.099 for all the measured data, 
whereas the maximum and minimum Fourier residuals in the 
unit cell were as low as +0.20/–0.19 e Å–3. Crystal data for 
compound (+)-2b at rt: C11H14N3O6, M = 284.429 amu, 
orthorhombic, space group P212121, nº 19, acentric, a = 
5.4380(7) Å, b = 10.423(2) Å, c = 22.933(3) Å, V = 1299.9(4) 
Å3, Z = 4, Z’ = 1; ρcalcd = 1.545 g cm–3, µ = 0.13 mm-1. The 
compound is chiral and crystallizes with an ordered water 
molecule in the asymmetric unit. CCDC 1060015 contains the 
supplementary crystallographic data for this paper. These data 
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can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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